obesity
108 all articles · 20 / page
Latest news
Tag
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests
A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.
Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end
An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide
A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.
Early 15% Weight Loss After Type 2 Diabetes Diagnosis Linked to Lower Complication Risk
In a large U.K. cohort, losing at least 15% of body weight within 2 years of type 2 diabetes diagnosis was linked to lower risks of heart, kidney, and eye complications, along with better glucose and blood pressure control.
Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip
Identifying High-Risk Children Safe for Same-Day Discharge After Tonsillectomy
Children with obesity and severe OSA usually stay overnight after tonsillectomy, but this study found most had no major complications. Oxygen nadir and AHI may help identify very low-risk patients who could be considered for same-day discha
Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes
Post-hoc metabolomic and lipidomic analyses from two phase 2 trials suggest retatrutide favorably remodels metabolic pathways linked to fatty acid oxidation, insulin resistance, and triglyceride composition in obesity, with and without type
Endocrine Profile in Pediatric Bardet-Biedl Syndrome: Insights from a Large Multidisciplinary Cohort
A retrospective study of 135 pediatric BBS patients reveals high prevalence of obesity (77.6%) and short stature (21.1%), with low rates of hypogonadism, hypothyroidism, and glucose metabolism disorders compared to adult populations.
Optimizing Delivery Timing for Obese Pregnancies: The Critical Role of Pre-Pregnancy Diabetes in Stillbirth Risk
A nationwide study reveals that pre-pregnancy BMI and diabetes status significantly influence gestational age-specific stillbirth risks, with obese diabetic women facing the highest absolute risks, necessitating tailored delivery timing str
Long-term Air Pollution Linked to Adverse Body Composition Changes in Older Adults with Metabolic Syndrome
A study of 1,454 older adults with metabolic syndrome reveals that long-term exposure to air pollutants like black carbon, PM2.5, and NO2 is associated with increased fat mass and decreased lean mass, persisting over three years, particular
Surgical Metabolic Intervention: Bariatric Surgery Transforms Outcomes in Type 1 Diabetes With Obesity
A multicenter retrospective cohort study reveals that metabolic bariatric surgery in 162 adults with type 1 diabetes and obesity achieved 29.7% weight loss at one year, reduced insulin requirements by 57%, and significantly improved glycemi
GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events
This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% re
Severe Obesity Triples Heart Failure Risk: New Insights from the Cross-Cohort Collaboration
A massive study of nearly 290,000 participants reveals that severe obesity (BMI ≥40) triples the risk of heart failure and nearly triples the risk of atrial fibrillation, with significant sex-based differences in stroke and mortality risk.
Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration
This review synthesizes findings from a 21- **Compiling final edits** Now that I’ve structured the article, I’m focusing on the final touches, particularly the content for the “Highlights,” “Expert Commentary,” and the “Conclusion” sections
Obesity Linked to Three-Fold Increase in Severe Infection Risk: A Global Analysis of 925 Pathogens
A large-scale multicohort study reveals that adult obesity significantly increases the risk of hospitalization and death across nearly 1,000 infectious diseases, accounting for approximately one in ten infection-related deaths globally.
Managing Obesity as a Chronic Disease: The 2026 WHO Guidelines on GLP-1 Therapies
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em